title: [Gaviscon in reflux symptoms. Results of a drug monitoring study].
abstract: 335 general practitioners participated in an observational study of the alginic acid-containing antacid preparation Gaviscon over a period of eight months. In this period, 2927 patients with reflux disease were treated. Some 62.3% of the patients were treated for six to eight days. Both the tablet and suspension forms of the drug were considered to be effective by both physician and patient in more than 94% of the cases. Drug toleration was also considered good in more than 95% of the cases. The taste of Gaviscon was described as good by 54.7% of the patients, and acceptable by 33.5%. Pregnant women with reflux symptoms were observed in a separate group (n = 52).
authors: Dr. Karl Thomae GmbH, Biberach an der Riss.
authors: H J
authors: HJ
authors: Hutt
authors: O
authors: O
authors: Tauber
authors: D
authors: D
authors: Flach
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000464:Alginates / Q000009:adverse effects / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000009:adverse effects / Q000627:therapeutic use*; D000863:Antacids / Q000627:therapeutic use*; D001639:Bicarbonates / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D012824:Silicic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D017693:Sodium Bicarbonate
chemical_list: D000464:Alginates; D000863:Antacids; D001639:Bicarbonates; D004338:Drug Combinations; D012824:Silicic Acid; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D017693:Sodium Bicarbonate
vernacular_title: Gaviscon bei Refluxbeschwerden. Ergebnisse eines Drug Monitoring.